PsiOxus Therapeutics nabbed £1.7 million ($2.7 million) from the U.K. government-backed Biomedical Catalyst to start a Phase I/II clinical trial of its cancer vaccine. The Ovarian Cancer Treated with AdenoVirus (OCTAVE) study will mark the second clinical trial of the oncolytic vaccine ColoAd1 for the treatment of platinum-resistant, recurrent ovarian cancer. More than 50 ovarian cancer patients will receive multiple doses of the vaccine and will be assessed for immunological responses as well as tumor response and survival. Release